Genocea Biosciences Inc., a Cambridge, Mass.-based biotechnology company, has raised $30 million dollars in a Series C financing round, adding the Bill & Melinda Gates Foundation to its investor list. Genocea, a maker of vaccines, plans to use the funding to advance its potential therapeutic vaccine for herpes simplex virus type 2, currently undergoing a Phase 1/2a study.
“We have made strong progress in our effort to create a new class of vaccines capable of combating serious infectious diseases that current vaccine discovery technologies cannot address,” stated Genocea CEO Chip Clark. “Completion of this financing round is a powerful vote of confidence from the financial community that will enable us to move aggressively to create new vaccines that will improve the health of patients around the world,” Clark added. In June 2012, he declared that the company planned to find a pharmaceutical company partner for the vaccine within the next year.
Date of Publication
July Donnelly, Boston Business Journal
Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.